EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Comparative Effectiveness of Botulinum Toxin a Versus Placebo for Neurogenic Overactive Bladder: A Meta‐Analysis

Konstantinos Tassoudis, Zachos Ioannis, Dimitropoulos Konstatninos, Evmorfopoulos Konstantinos, Marsitopoulos Konstantinos, Vassilios Tassoudis, Vassilios Tzortzis

Neurourology and Urodynamics · 2026

DOI: 10.1002/nau.70211 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Neurourology and Urodynamics, 2026. Verfasst von Konstantinos Tassoudis und 6 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital of Larissa, Larissa, Greece. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Urinary Bladder, Overactive, Urinary Bladder, Neurogenic, Urinary Bladder. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lower urinary tract (LUT) dysfunctions affect millions of patients globally. LUT dysfunctions are extremely common in patients with neurological diseases. Worldwide, subtype A of Botulinum Toxin A (BTXA) is regularly used to treat these disorders.

Introduction

LUT dysfunctions have various patterns of expression. The most prevalent of these is neurogenic detrusor overactivity (NDO), which is strongly associated with neurological diseases and can significantly impact a patient's life.

Objective

Onabotulinumtoxin A is a widely used drug for the treatment of neurogenic bladder. The purpose of this study is to evaluate its efficacy and safety across different dosages in patients with the condition. Data Sources Pubmed, Scopus, Web of Science. Review Methods Systematic literature review was performed to identify randomized, double‐blind, placebo‐controlled trials of onabotulinumtoxin A for NDO. Seven randomized controlled trials were incorporated in this meta‐analysis. The primary outcome concerned urodynamic parameters, including Maximum Cystometric Capacity (MCC) and Maximum Detrusor Pressure (MDP); the mean number of Urinary Incontinence (UI) episodes per week was also assessed. Safety was evaluated by the incidence of various Adverse Events (AE). Data was extracted by two authors and statistical analysis was carried out using the Statistical Package for the Social Sciences (SPSS v.29).

Results

Seven RCTs involving 1592 patients in total were included in the study, following screening of 1602 potentially relevant articles. The Onabotulinumtoxin A—treated groups showed a significant increase in MCC (Mean Difference ([MD]: 128.866, 95% Confidence Interval [CI]: 98.836, 158.896, p < 0.001, in the group that received 200 Units of Onabotulinumtoxin A; MD: 151.389, CI: 106.006, 196.773, p < 0.005, in the group that received 300Units of Onabotulinumtoxin A). There was also a significant decrease in MDP in the Onabotulinumtoxin A‐treated groups (MD: −29.051, CI: −39.557, −18.545, p < 0.002, 200 U group; MD: −31.751, CI: −45.226, −18.276, p < 0.01, 300 U group). Additionally, no effect was noticed in the mean number of UI episodes per week (MD: −10.69, 95% CI: −33.86, 12.49, p = 0.11; MD: −10.55, 95% CI: −59.06, 37.97, p = 0.22, 200 U and 300 U respectively). Taking AEs into consideration, Onabotulinumtoxin A‐treated groups were often associated with more complications, including urinary tract infections (UTI) (LogOR: 0.341, CI: 0.011, 0.67, p = 0.045, 200 U group; LogOR: 0.424, CI: 0.075, 0.773, p = 0.028, 300 U group) and urinary retention (UR) (LogOR: 1.746, CI: 0.869, 2.623, p = 0.008, 200 U group; LogOR: 1.879, CI: 0.679, 3.078, p = 0.021, 300 U group).

Conclusions

Our meta‐analyses found that Onabotulinumtoxin A can be beneficial in improving the urodynamic parameters (MCC and MDP). As far as safety is concerned, the drug‐treated groups had a slightly higher likelihood of developing UTI or UR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type AUrinary Bladder, OveractiveUrinary Bladder, NeurogenicUrinary BladderAcetylcholine Release InhibitorsNeuromuscular AgentsHumansTreatment OutcomeUrodynamicsRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

bladderbotulinumneurogenicoveractivetoxin

Substanzen

Botulinum Toxins, Type Aonabotulinum toxin AAcetylcholine Release InhibitorsNeuromuscular Agents

Autor:innen und Institutionen

  • University Hospital of Larissa, Larissa, Greece.

Zitieren

APA

Tassoudis, K., Ioannis, Z., Konstatninos, D., Konstantinos, E., Konstantinos, M., Tassoudis, V., & Tzortzis, V. (2026). Comparative Effectiveness of Botulinum Toxin a Versus Placebo for Neurogenic Overactive Bladder: A Meta‐Analysis. Neurourology and Urodynamics. https://doi.org/10.1002/nau.70211

Vancouver

Tassoudis K, Ioannis Z, Konstatninos D, Konstantinos E, Konstantinos M, Tassoudis V, et al. Comparative Effectiveness of Botulinum Toxin a Versus Placebo for Neurogenic Overactive Bladder: A Meta‐Analysis. Neurourology and Urodynamics. 2026. doi:10.1002/nau.70211

BibTeX
@article{Tassoudis2026,
  author = {Tassoudis, Konstantinos and Ioannis, Zachos and Konstatninos, Dimitropoulos and Konstantinos, Evmorfopoulos and Konstantinos, Marsitopoulos and Tassoudis, Vassilios and Tzortzis, Vassilios},
  title = {Comparative Effectiveness of Botulinum Toxin a Versus Placebo for Neurogenic Overactive Bladder: A Meta‐Analysis},
  journal = {Neurourology and Urodynamics},
  year = {2026},
  doi = {10.1002/nau.70211}
}
Kostenlos starten →